Stryker (NYSE:SYK) Stock Price Expected to Rise, Truist Financial Analyst Says

Stryker (NYSE:SYK) had its price target hoisted by research analysts at Truist Financial from $392.00 to $400.00 in a research report issued on Friday, Marketbeat reports. The brokerage currently has a “hold” rating on the medical technology company’s stock. Truist Financial’s target price points to a potential upside of 10.38% from the stock’s previous close.

SYK has been the topic of several other research reports. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Barclays lifted their price target on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Wells Fargo & Company increased their price objective on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday. UBS Group set a $408.00 target price on Stryker in a research report on Monday, October 13th. Finally, Weiss Ratings cut Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, November 7th. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Stock Performance

NYSE:SYK opened at $362.39 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a market capitalization of $138.59 billion, a PE ratio of 48.00, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a fifty day moving average of $371.96 and a two-hundred day moving average of $381.22.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the company earned $2.87 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, research analysts forecast that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 520,500 shares of company stock worth $184,803,065. Insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Institutional investors have recently bought and sold shares of the business. Creative Planning boosted its position in shares of Stryker by 3.2% during the 3rd quarter. Creative Planning now owns 89,888 shares of the medical technology company’s stock worth $33,229,000 after acquiring an additional 2,786 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Stryker by 4.9% during the 3rd quarter. Lazard Asset Management LLC now owns 55,526 shares of the medical technology company’s stock worth $20,526,000 after buying an additional 2,608 shares during the last quarter. AQR Capital Management LLC lifted its position in Stryker by 10.4% in the third quarter. AQR Capital Management LLC now owns 136,256 shares of the medical technology company’s stock valued at $50,370,000 after acquiring an additional 12,866 shares during the last quarter. Zacks Investment Management boosted its position in shares of Stryker by 4.4% in the 3rd quarter. Zacks Investment Management now owns 71,679 shares of the medical technology company’s stock valued at $26,498,000 after purchasing an additional 3,039 shares during the period. Finally, Credit Agricole S A acquired a new stake in shares of Stryker in the third quarter valued at approximately $194,045,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.